IPR
The TRIPS waiver on Covid-19 pharmaceuticals and the Big Pharma
June 2, 2021
There is a raging debate about whether or not the WTO should temporarily waive some intellectual property rights of Covid-19 pharmaceuticals. Developed countries oppose the proposal, but recently the US has announced its limited support, while the EU continues to wrangle over its necessity. For proponents, the waiver would speed up and scale up vaccine production and contribute to a faster vaccination process in poorer countries.
Rethink RCEP, liberalization, ASEAN told
April 20, 2017
Research group IBON today asked the Philippine government and other members of the Association of Southeast Asian Nation (ASEAN) to rethink plans of further deepening economic liberalization. This has only caused unprecedented production decline, poverty and joblessness while undermining national sovereignty, development planning, and public welfare and interest in the country and region. IBON […]
